

Patent
Attorney's Docket No. 017753-094

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Jean-Marc BALLOUL et al.) Group Art Unit: 1652
Application No.: 09/043,933) Examiner: A. Salimi
Filed: March 30, 1998)
For: PHARMACEUTICAL COMPOSITION)
FOR TREATING PAPILLOMAVIRUS)
TUMORS AND INFECTION)

REPLY TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 7, 1999, please enter the following
remarks:

REMARKS

This Reply is responsive the Office Action dated May 7, 1999, which requires that the application comply with the sequence rules as set forth in 37 CFR §§ 1.821-1.825, and sets forth a restriction requirement under 35 U.S.C. §§ 121 and 372.

Firstly, applicants note that submitted herewith is a copy of the sequence listing in computer readable form, a statement that the computer readable and paper copies are the same, and a declaration indicating that the submissions contain no new matter. Also submitted separately is an amendment entering the substitute paper copy into the